A Phase 1, Randomized, Single-center, Open-label, Three-sequence, Three-period, Three-treatment Crossover Study to Evaluate the Effect of Food on the Single-dose Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability of Sotagliflozin Oral Tablet to Oral Solution in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 22 Sep 2017
At a glance
- Drugs Sotagliflozin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Sanofi
- 19 Sep 2017 Status changed from active, no longer recruiting to completed.
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Aug 2017 Planned End Date changed from 1 Aug 2017 to 7 Sep 2017.